Alexion’s CEO search is over. The Connecticut biotech, which bade its skipper farewell late last year, is bringing former Baxalta chief Ludwig Hantson into the…

Patient-access groups that have targeted Gilead's Sovaldi IP all over the world are back on the attack in Europe.

Psoriasis is a visible skin condition, but to J&J that's only half the story. The company wants to tell the full story of psoriasis' impact.

Sanofi is reportedly putting its newly bulked-up consumer healthcare media buying account into play.

With the FDA's approval of Purdue and Shionogi's Symproic, there's now a third competitor prepping to jump into the opioid-induced constipation…

Eli Lilly CEO David A. Ricks today announced an $85 million expansion of Lilly diabetes med manufacturing operations in Indianapolis.

Eli Lilly suffered the failure of its long-anticipated Alzheimer’s compound solanezumab and faced falling demand for key blockbusters last year. Nevertheless,…

China plans to eliminate major regulatory barriers for foreign drugs, Tessa bought Euchloe for its checkpoint inhibitors, and J&J and Lilly CEOs supported…

Pharma